

# FACT SHEET

## COMPANY PROFILE


Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 4,823 employees (as of 30 September 2019) worldwide, the Group generated revenue of EUR 2,089.3m in fiscal year 2022/23 (as of 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

## SHARE CHART



## SHAREHOLDER STRUCTURE



## MANAGEMENT BOARD



**Dr. Markus Weber**  
CEO



**Justus Felix Wehmer**  
CFO

## SUPERVISORY BOARD

- › Dr. Karl Lamprecht
- › Falk Bindheim
- › Isabel De Paoli
- › Peter Kameritsch
- › Heike Madan
- › Dr. Christian Müller
- › Torsten Reitze
- › René Denner
- › Stefan Müller
- › Tania von der Goltz
- › Brigitte Koblizek
- › Jeffrey Marx
- › Dr. Christian Münster

## STOCK FUNDAMENTALS

ISIN	DE0005313704
WKN	531370
Share type	Ordinary
Bloomberg Code	AFX@GR
Reuters Code	AFXG.DE
Ticker	AFX
Branch	Medical Technology
Index	MDAX, TecDAX
Segment	Prime Standard
Last Dividend	1.10 EUR (2022/23)
No. of shares	89.440.570
Market Cap	EUR 5.09 bn
52 week high	123.75 EUR
52 week low	54.60 EUR

## FINANCIAL CALENDAR

<b>Dec 11, 2024</b>	Publication annual financial report
<b>Feb 12, 2025</b>	Press Release - quarterly statement (call-date Q1)
<b>Mar 26, 2025</b>	Annual General Meeting
<b>May 14, 2025</b>	Publication half-yearly financial report
<b>Aug 07, 2025</b>	Press Release - quarterly statement (call-date Q3)
<b>Dec 11, 2025</b>	Publication annual financial report

# FACT SHEET

## HIGHLIGHTS ON A YEARLY BASIS<sup>1</sup>

	2022/23		2021/22		2020/21		2019/20	
	€m	%	€m	%	€m	%	€m	%
Revenue	2,089.3	100	1,902.8	100	1,646.8	100	1,335.5	100
Research and development expenses	349.3	16.7	291.4	15.3	232.1	14.1	218.8	16.4
EBIT	348.1	16.7	396.9	20.9	373.6	22.7	177.6	13.3
Consolidated profit <sup>1</sup>	292.0	14.0	295.9	15.6	237.5	14.4	123.4	9.2
Earnings per share <sup>2</sup> (in €)	3.25		3.29		2.64		1.37	
Dividend per share (in €)	1.10 <sup>3</sup>		1.10 <sup>3</sup>		0.90 <sup>3</sup>		0.50 <sup>3</sup>	
Cash flows from operating activities	250.9		188.2		362.7		178.5	
Cash flows from investing activities	-111.0		-148.9		-71.2		-71.9	
Cash flows from financing activities	-135.1		-38.2		-289.9		-123.0	
Total assets	3,032.9	100	2,822.8	100	2,396.0	100	2,013.3	100
Property, plant and equipment	315.8	10.4	236.1	8.4	199.6	8.3	135.3	6.7
Equity	2,172.9	71.6	2,030.1	71.9	1,677.4	70.0	1,450.6	72.0
Net cash <sup>4</sup>	863.9	28.5	885.6	30.3	939.9	39.2	707.2	35.1
Employees at end of reporting period (30 September)	4,823		4,224		3,531		3,290	

<sup>1</sup> Before non-controlling interests

<sup>2</sup> Profit/(loss) per share attributable to the shareholders of the parent company in the fiscal year

<sup>3</sup> Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG

<sup>4</sup> Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG

### Carl Zeiss Meditec AG

Göschwitzer Str. 51-52  
07745 Jena  
Deutschland  
[www.zeiss.de/meditec-ag/ir](http://www.zeiss.de/meditec-ag/ir)  
[investors.med@zeiss.com](mailto:investors.med@zeiss.com)

### Contact Investor Relations

Sebastian Frericks  
Investor Relations  
Phone: +49 (0) 36 41 / 2 20 -1 16  
Fax: +49 (0) 36 41 2 20 - 1 17  
E-Mail: [investors.med@zeiss.com](mailto:investors.med@zeiss.com)